Nanotherapeutics for the Myocardium: A Potential Alternative for Treating Cardiac Diseases.
Journal
Journal of cardiovascular pharmacology
ISSN: 1533-4023
Titre abrégé: J Cardiovasc Pharmacol
Pays: United States
ID NLM: 7902492
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
12
12
2022
accepted:
03
06
2023
medline:
11
9
2023
pubmed:
21
6
2023
entrez:
21
6
2023
Statut:
epublish
Résumé
Cardiovascular diseases (CVDs) are the foremost cause of morbidity and mortality worldwide. Current clinical interventions include invasive approaches for progressed conditions and pharmacological assistance for initial stages, which has systemic side effects. Preventive, curative, diagnostic, and theranostic (therapeutic + diagnostic) approaches till date are not very useful in combating the ongoing CVD epidemic, which demands a promising efficient alternative approach. To combat the growing CVD outbreak globally, the ideal strategy is to make the therapeutic intervention least invasive and direct to the heart to reduce the bystander effects on other organs and increase the bioavailability of the therapeutics to the myocardium. The application of nanoscience and nanoparticle-mediated approaches have gained a lot of momentum because of their efficient passive and active myocardium targeting capability owing to their improved specificity and controlled release. This review provides extensive insight into the various types of nanoparticles available for CVDs, their mechanisms of targeting (eg, direct or indirect), and the utmost need for further development of bench-to-bedside cardiac tissue-based nanomedicines. Furthermore, the review aims to summarize the different ideas and methods of nanoparticle-mediated therapeutic approaches to the myocardium till date with present clinical trials and future perspectives. This review also reflects the potential of such nanoparticle-mediated tissue-targeted therapies to contribute to the sustainable development goals of good health and well-being.
Identifiants
pubmed: 37341530
doi: 10.1097/FJC.0000000000001444
pii: 00005344-990000000-00188
doi:
Banques de données
ClinicalTrials.gov
['NCT05032937']
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
180-188Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Iafisco M, Alogna A, Miragoli M, et al. Cardiovascular nanomedicine: the route ahead. Nanomedicine (Lond). 2019;14:2391–2394.
Psaltopoulou T, Hatzis G, Papageorgiou N, et al. Socioeconomic status and risk factors for cardiovascular disease: impact of dietary mediators. Hellenic J Cardiol. 2017;58:32–42.
Okereke OI, Manson JE. Psychosocial factors and cardiovascular disease risk: an opportunity in women's health. Circ Res. 2017;120:1855–1856.
Faraday MX. The Bakerian lecture—experimental relations of gold (and other metals) to light. Philos Trans R Soc Lond. 1857;147:145–181.
Seqqat R, Blaney L, Quesada D, et al. Nanoparticles for environment, engineering, and nanomedicine. J Nanotechnol. 2019;2019:2850723.
Gentemann L, Kalies S, Coffee M, et al. Modulation of cardiomyocyte activity using pulsed laser irradiated gold nanoparticles. Biomed Opt Express. 2017;8:177–192.
Aljabali AA, Al-Trad B, Al Gazo L, et al. Gold nanoparticles ameliorate diabetic cardiomyopathy in streptozotocin-induced diabetic rats. J Mol Struct. 2021;1231:130009.
Henson JC, Brickell A, Kim JW, et al. PEGylated gold nanoparticle toxicity in cardiomyocytes: assessment of size, concentration, and time dependency. IEEE Trans Nanobioscience. 2022;21:387–394.
Mosselhy DA, He W, Li D, et al. Silver nanoparticles: in vivo toxicity in zebrafish embryos and a comparison to silver nitrate. J Nanopart Res. 2016;18:1–5.
Rosas-Hernández H, Jiménez-Badillo S, Martínez-Cuevas PP, et al. Effects of 45-nm silver nanoparticles on coronary endothelial cells and isolated rat aortic rings. Toxicol Lett. 2009;191:305–313.
Manuel AR, Martinez-Cuevas PP, Rosas-Hernandez H, et al. Evaluation of vascular tone and cardiac contractility in response to silver nanoparticles, using Langendorff rat heart preparation. Nanomedicine. 2017;13:1507–1518.
Lotfy MM, Dowidar MF, Ali HA, et al. Effect of selenium nanoparticles and/or bee venom against stz-induced diabetic cardiomyopathy and nephropathy. Metabolites. 2023;13:400.
Xiao S, Mao L, Xiao J, et al. Selenium nanoparticles inhibit the formation of atherosclerosis in apolipoprotein E deficient mice by alleviating hyperlipidemia and oxidative stress. Eur J Pharmacol. 2021;902:174120.
Xiong F, Wang H, et al. Cardioprotective activity of iron oxide nanoparticles. Sci Rep. 2015;5:8579.
Dong P, Wang H, Xing S, et al. Fluorescent magnetic iron oxide nanoparticleencapsulated protein hydrogel against doxorubicin-associated cardiotoxicity and for enhanced cardiomyocyte survival. J Biomed Nanotechnol. 2020;16:922–930.
Luo C, Li Y, Yang L, et al. Superparamagnetic iron oxide nanoparticles exacerbate the risks of reactive oxygen species-mediated external stresses. Arch Toxicol. 2015;89:357–369.
Zheng H, You J, Yao X, et al. Superparamagnetic iron oxide nanoparticles promote ferroptosis of ischemic cardiomyocytes. J Cell Mol Med. 2020;24:11030–11033.
Chowdhury S, Toth I, Stephenson RJ. Dendrimers in vaccine delivery: recent progress and advances. Biomaterials. 2022;280:121303.
Najafi F, Salami-Kalajahi M, Roghani-Mamaqani H, et al. Effect of grafting ratio of poly (propylene imine) dendrimer onto gold nanoparticles on the properties of colloidal hybrids, their DOX loading and release behavior and cytotoxicity. Colloids Surf B Biointerfaces. 2019;178:500–507.
Abedi-Gaballu F, Dehghan G, Ghaffari M, et al. PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl Mater Today. 2018;12:177–190.
Golshan M, Salami-Kalajahi M, Mirshekarpour M, et al. Synthesis and characterization of poly (propylene imine)-dendrimer-grafted gold nanoparticles as nanocarriers of doxorubicin. Colloids Surf B Biointerfaces. 2017;155:257–265.
Sun Y, Jiao Y, Wang Y, et al. The strategy to improve gene transfection efficiency and biocompatibility of hyperbranched PAMAM with the cooperation of PEGylated hyperbranched PAMAM. Int J Pharm. 2014;465:112–119.
Shah A, Viola H, Kretzmann J, et al. Testing efficacy of branched dendrimers for the delivery of a peptide into cardiomyocytes. Heart Lung Circ. 2018;27:S136.
Liu J, Gu C, Cabigas EB, et al. Functionalized dendrimer-based delivery of angiotensin type 1 receptor siRNA for preserving cardiac function following infarction. Biomaterials. 2013;34:3729–3736.
Qi J, Zhuang J, Lu Y, et al. In vivo fate of lipid-based nanoparticles. Drug Discov Today. 2017;22:166–172.
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:1–9.
Vinhas R, Mendes R, Fernandes AR, et al. Nanoparticles—emerging potential for managing leukemia and lymphoma. Front Bioeng Biotechnol. 2017;5:79.
Saludas L, Pascual-Gil S, Roli F, et al. Heart tissue repair and cardioprotection using drug delivery systems. Maturitas. 2018;110:1–9.
Cheraghi M, Negahdari B, Daraee H, et al. Heart targeted nanoliposomal/nanoparticles drug delivery: an updated review. Biomed Pharmacother. 2017;86:316–323.
Paulis LE, Geelen T, Kuhlmann MT, et al. Distribution of lipid-based nanoparticles to infarcted myocardium with potential application for MRI-monitored drug delivery. J Control Release. 2012;162:276–285.
Katsuki S, Matoba T, Koga JI, et al. Anti-inflammatory nanomedicine for cardiovascular disease. Front Cardiovasc Med. 2017;4:87.
Sajid MI, Jamshaid U, Jamshaid T, et al. Carbon nanotubes from synthesis to in vivo biomedical applications. Int J Pharm. 2016;501:278–299.
Zhang W, Zhang Z, Zhang Y. The application of carbon nanotubes in target drug delivery systems for cancer therapies. Nanoscale Res Lett. 2011;6:1–22.
McCauley MD, Vitale F, Yan JS, et al. In vivo restoration of myocardial conduction with carbon nanotube fibers. Circ Arrhythm Electrophysiol. 2019;12():e007256.
Hitscherich P, Aphale A, Gordan R, et al. Electroactive graphene composite scaffolds for cardiac tissue engineering. J Biomed Mater Res A. 2018;106:2923–2933.
Shin SR, Zihlmann C, Akbari M, et al. Reduced graphene oxide-gelMA hybrid hydrogels as scaffolds for cardiac tissue engineering. Small. 2016;12:3677–3689.
Paul A, Hasan A, Kindi HA, et al. Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair. ACS Nano. 2014;8:8050–8062.
Bhatnagar D, Kumar V, Kumar A, et al. Graphene quantum dots FRET based sensor for early detection of heart attack in human. Biosens Bioelectron. 2016;79:495–499.
Prajnamitra RP, Chen HC, Lin CJ, et al. Nanotechnology approaches in tackling cardiovascular diseases. Molecules. 2019;24:2017.
Horwitz LD, Kaufman D, Keller MW, et al. Time course of coronary endothelial healing after injury due to ischemia and reperfusion. Circulation. 1994;90:2439–2447.
Kim N, Ullah I, Chung K, et al. Targeted delivery of recombinant heat shock protein 27 to cardiomyocytes promotes recovery from myocardial infarction. Mol Pharm. 2020;17:2034–2043.
Kopechek JA, McTiernan CF, Chen X, et al. Ultrasound and microbubble-targeted delivery of a microRNA inhibitor to the heart suppresses cardiac hypertrophy and preserves cardiac function. Theranostics. 2019;9:7088–7098.
Cheng K, Shen D, Hensley MT, et al. Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting. Nat Commun. 2014;5:4880.
Zhang H, Li N, Sirish P, et al. The cargo of CRPPR-conjugated liposomes crosses the intact murine cardiac endothelium. J Control Release. 2012;163:10–17.
Kanki S, Jaalouk DE, Lee S, et al. Identification of targeting peptides for ischemic myocardium by in vivo phage display. J Mol Cell Cardiol. 2011;50:841–848.
Rana S, Datta K, Reddy TL, et al. A spatio-temporal cardiomyocyte targeted vector system for efficient delivery of therapeutic payloads to regress cardiac hypertrophy abating bystander effect. J Control Release. 2015;200:167–178.
Banai S, Shweiki D, Pinson A, et al. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res. 1994;28:1176–1179.
Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–1309.
Nguyen MM, Carlini AS, Chien MP, et al. Enzyme-responsive nanoparticles for targeted accumulation and prolonged retention in heart tissue after myocardial infarction. Adv Mater. 2015;27:5547–5552.
Chang MY, Yang YJ, Chang CH, et al. Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction. J Control Release. 2013;170:287–294.
Sekuła-Stryjewska M, Noga S, Dźwigońska M, et al. Graphene-based materials enhance cardiomyogenic and angiogenic differentiation capacity of human mesenchymal stem cells in vitro–focus on cardiac tissue regeneration. Mater Sci Eng C Mater Biol Appl. 2021;119:111614.
Kimura T, Ferran B, Tsukahara Y, et al. Production of adeno-associated virus vectors for in vitro and in vivo applications. Sci Rep. 2019;9:1–13.
Kohama Y, Higo S, Masumura Y, et al. Adeno-associated virus-mediated gene delivery promotes S-phase entry-independent precise targeted integration in cardiomyocytes. Sci Rep. 2020;10:1–13.
Liu Z, Klose K, Neuber S, et al. Comparative analysis of adeno-associated virus serotypes for gene transfer in organotypic heart slices. J Transl Med. 2020;18:1–12.
Gabisonia K, Prosdocimo G, Aquaro GD, et al. MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs. Nature. 2019;569:418–422.
Gao G, Bish LT, Sleeper MM, et al. Transendocardial delivery of AAV6 results in highly efficient and global cardiac gene transfer in rhesus macaques. Hum Gene Ther. 2011;22:979–984.
Kim SH, Jeong JH, Ou M, et al. Cardiomyocyte-targeted siRNA delivery by prostaglandin E2-Fas siRNA polyplexes formulated with reducible poly (amido amine) for preventing cardiomyocyte apoptosis. Biomaterials. 2008;29:4439–4446.
Funkhouser J. Reinventing pharma: the theranostic revolution. Curr Drug Discov. 2002;2:17–19.
Kopechek JA, Carson AR, McTiernan CF, et al. Cardiac gene expression knockdown using small inhibitory RNA-loaded microbubbles and ultrasound. PLoS One. 2016;11():e0159751.
Gill SL, O'Neill H, McCoy RJ, et al. Enhanced delivery of microRNA mimics to cardiomyocytes using ultrasound responsive microbubbles reverses hypertrophy in an in-vitro model. Technol Health Care. 2014;22:37–51.
Xue X, Shi X, Dong H, et al. Delivery of microRNA-1 inhibitor by dendrimer-based nanovector: an early targeting therapy for myocardial infarction in mice. Nanomedicine. 2018;14:619–631.
Zhang L, Hoffman JA, Ruoslahti E. Molecular profiling of heart endothelial cells. Circulation. 2005;112:1601–1611.
Yang Y, Shi C, Hou X, et al. Modified VEGF targets the ischemic myocardium and promotes functional recovery after myocardial infarction. J Control Release. 2015;213:27–35.
Wang Y, Ding N, Guan G, et al. Rapid delivery of Hsa-miR-590-3p using targeted exosomes to treat acute myocardial infarction through regulation of the cell cycle. J Biomed Nanotechnol. 2018;14:968–977.
Huang Z, Song Y, Pang Z, et al. Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles. Int J Nanomedicine. 2017;12:3023–3036.
McGuire MJ, Samli KN, Johnston SA, et al. In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo. J Mol Biol. 2004;342:171–182.
Nam HY, McGinn A, Kim PH, et al. Primary cardiomyocyte-targeted bioreducible polymer for efficient gene delivery to the myocardium. Biomaterials. 2010;31:8081–8087.
Zhao X, Luo W, Hu J, et al. Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy. J Nanobiotechnology. 2018;16:1–14.
Iswanti FC, Nurulita I, Djauzi S, et al. Preparation, characterization, and evaluation of chitosan-based nanoparticles as CpG ODN carriers. Biotechnol Biotechnol Equip. 2019;33:390–396.
Rana S, Datta R, Chaudhuri RD, et al. Nanotized PPARα overexpression targeted to hypertrophied myocardium improves cardiac function by attenuating the p53-GSK3β-mediated mitochondrial death pathway. Antioxid Redox Signal. 2019;30:713–732.
Chuan D, Jin T, Fan R, et al. Chitosan for gene delivery: methods for improvement and applications. Adv Colloid Interf Sci. 2019;268:25–38.
Sanyakamdhorn S, Agudelo D, Tajmir-Riahi HA. Encapsulation of antitumor drug doxorubicin and its analogue by chitosan nanoparticles. Biomacromolecules. 2013;14:557–563.
Ray A, Rana S, Banerjee D, et al. Improved bioavailability of targeted curcumin delivery efficiently regressed cardiac hypertrophy by modulating apoptotic load within cardiac microenvironment. Toxicol Appl Pharmacol. 2016;290:54–65.
Chatterjee E, Chaudhuri RD, Sarkar S. Cardiomyocyte targeted overexpression of IGF1 during detraining restores compromised cardiac condition via mTORC2 mediated switching of PKCδ to PKCα. Biochim Biophys Acta Mol Basis Dis. 2019;1865:2736–2752.
Banerjee D, Chaudhuri RD, Niyogi S, et al. Metabolic impairment in response to early induction of C/EBPβ leads to compromised cardiac function during pathological hypertrophy. J Mol Cell Cardiol. 2020;139:148–163.
Chaudhuri RD, Banik A, Mandal B, et al. Cardiac-specific overexpression of HIF-1α during acute myocardial infarction ameliorates cardiomyocyte apoptosis via differential regulation of hypoxia-inducible pro-apoptotic and anti-oxidative genes. Biochem Biophys Res Commun. 2021;537:100–108.
Wen Z, Zhan J, Li H, et al. Dual-ligand supramolecular nanofibers inspired by the renin-angiotensin system for the targeting and synergistic therapy of myocardial infarction. Theranostics. 2021;11:3725–3741.
Kang JY, Kim H, Mun D, et al. Co-delivery of curcumin and miRNA-144-3p using heart-targeted extracellular vesicles enhances the therapeutic efficacy for myocardial infarction. J Control Release. 2021;331:62–73.
Ikeda G, Matoba T, Ishikita A, et al. Nanoparticle-mediated simultaneous targeting of mitochondrial injury and inflammation attenuates myocardial ischemia-reperfusion injury. J Am Heart Assoc. 2021;10():e019521.
Mostafa F, Abdel-Moneim A, Abdul-Hamid M, et al. Polydatin and polydatin-loaded chitosan nanoparticles attenuate diabetic cardiomyopathy in rats. J Mol Histol. 2021;52:135–152.
Zhang Y, Yin Y, Zhang W, et al. Reactive oxygen species scavenging and inflammation mitigation enabled by biomimetic Prussian blue analogues boycott atherosclerosis. J Nanobiotechnology. 2021;19:1–3.
Mansukhani NA, Peters EB, So MM, et al. Peptide amphiphile supramolecular nanostructures as a targeted therapy for atherosclerosis. Macromol Biosci. 2019;19:e1900066.
Toita R, Kawano T, Murata M, et al. Bioinspired macrophage-targeted anti-inflammatory nanomedicine: a therapeutic option for the treatment of myocarditis. Mater Sci Eng C Mater Biol Appl. 2021;131:112492.
Lakshmanan R, Maulik N. Development of next generation cardiovascular therapeutics through bio-assisted nanotechnology. J Biomed Mater Res B Appl Biomater. 2018;106:2072–2083.
Bobo D, Robinson KJ, Islam J, et al. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33:2373–2387.
Galagudza MM, Korolev DV, Sonin DL, et al. Targeted drug delivery into reversibly injured myocardium with silica nanoparticles: surface functionalization, natural biodistribution, and acute toxicity. Int J Nanomedicine. 2010;5:231–237.
Feynman RichardP. There's plenty of room at the bottom. Eng Sci. 1960;23:22–36.
Chong JJ, Yang X, Don CW, et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature. 2014;510:273–277.
Zhou LS, Zhao GL, Liu Q, et al. Silencing collapsin response mediator protein-2 reprograms macrophage phenotype and improves infarct healing in experimental myocardial infarction model. J Inflamm (Lond). 2015;12:1–12.
Somasuntharam I, Boopathy AV, Khan RS, et al. Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving cardiac function following myocardial infarction. Biomaterials. 2013;34:7790–7798.